Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rγnull (NOG) mice

  • Authors:
    • Kenji Hamada
    • Makoto Monnai
    • Kenji Kawai
    • Chiyoko Nishime
    • Chika Kito
    • Noriyuki Miyazaki
    • Yasuyuki Ohnishi
    • Masato Nakamura
    • Hiroshi Suemizu
  • View Affiliations

  • Published online on: January 1, 2008     https://doi.org/10.3892/ijo.32.1.153
  • Pages: 153-159
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To examine the drug efficacy of a novel farnesyltransferase inhibitor (FTI), CH4512600, in vivo, we developed a reliable liver metastasis model of human colon cancer using NOD/Shi-scid IL2Rγnull (NOG) mice. Eleven human colon cancer cell lines were examined for their ability to form diverse metastatic foci in the livers of NOG mice. When inoculated with 104 COLO320DM, HCT 116, HT-29, WiDr, LoVo and LS174T cells, liver metastasis was evident in 100% (6/6), 100% (6/6), 88.9% (8/9), 87.5% (7/8), 83.3% (5/6) and 50.0% (3/6) of the NOG mice, respectively. CaCo2, COLO201, LS123, SW48 and SW1417 showed no metastasis when seeded at 104 cells even in NOG mice. The mRNA expression levels and genetic mutations of N, H and K-RAS genes, which directly affect the levels of cellular RAS protein that would be molecular target for FTI, were also examined in these six metastatic human colon cancer cell lines for molecular biological and genotypic characteristics. Only three cell lines had a point mutation in the RAS oncogene. LS174T cell line had a point mutation of the K-RAS gene at codon 12 (gly12↷asp; G12D), and HCT 116 and LoVo cell lines had a point mutation of the K-RAS gene at codon 13 (gly13↷asp; G13D). Relative gene expression levels of N, H and K-RAS genes in the HCT 116 cell line were 2.6-5.0-fold lower than that of LS174T and LoVo cell lines. We selected HCT 116 cell line from our liver metastasis model for evaluation of FTI CH4512600 efficacy in vivo. Using the NOG mouse liver metastasis model, we demonstrated the effectiveness of FTI CH4512600 to suppress tumor growth in vivo and to prolong mouse survival significantly from 36.9±2.9 to 50.3±9.4 days.

Related Articles

Journal Cover

January 2008
Volume 32 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Hamada, K., Monnai, M., Kawai, K., Nishime, C., Kito, C., Miyazaki, N. ... Suemizu, H. (2008). Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rγnull (NOG) mice. International Journal of Oncology, 32, 153-159. https://doi.org/10.3892/ijo.32.1.153
MLA
Hamada, K., Monnai, M., Kawai, K., Nishime, C., Kito, C., Miyazaki, N., Ohnishi, Y., Nakamura, M., Suemizu, H."Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rγnull (NOG) mice". International Journal of Oncology 32.1 (2008): 153-159.
Chicago
Hamada, K., Monnai, M., Kawai, K., Nishime, C., Kito, C., Miyazaki, N., Ohnishi, Y., Nakamura, M., Suemizu, H."Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rγnull (NOG) mice". International Journal of Oncology 32, no. 1 (2008): 153-159. https://doi.org/10.3892/ijo.32.1.153